1165740-62-4
1165740-62-4 structure
- Name: Vorsetuzumab
- Chemical Name: Vorsetuzumab
- CAS Number: 1165740-62-4
- Molecular Formula:
- Molecular Weight: 146.1 (kDa)
- Catalog: Research Areas Cancer
- Create Date: 2023-01-20 13:05:43
- Modify Date: 2025-08-25 14:02:27
-
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1].
| Name | Vorsetuzumab |
|---|
| Description | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1]. |
|---|---|
| Related Catalog | |
| Target |
CD70[1] |
| In Vitro | Vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1]. |
| In Vivo | Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1]. Animal Model: Burkitt’s lymphoma xenograft model in SRG mice[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; every other day; for 12 d Result: Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg). |
| References |
| Molecular Weight | 146.1 (kDa) |
|---|